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Cross-Reactive 
Antibodies to 
Pandemic (H1N1) 
2009 Virus, 
Singapore 
To the Editor: Accumulating 
evidence suggests that the degree 
of serologic cross-reactivity to pan-
demic (H1N1) 2009 virus varies be-
tween populations worldwide. To 
assess potential serologic cross-reac-
tivity in Singapore, we obtained se-
rum samples during May–June 2009 
from 50 randomly recruited, healthy 
volunteers born mostly before 1958 
(i.e., potentially those with some 
natural exposure to the then circulat-
ing H1N1/1918-like subtype viruses) 
before widespread transmission of 
pandemic (H1N1) 2009 virus in Sin-
gapore. Standard serologic hemagglu-
tination-inhibition (HI) tests (1) were 
performed in 2 reference laboratories 
(Singapore during July–October 2009 
and Melbourne, Australia, in January 
2010), and microneutralization (MN) 
tests (2) were performed in 1 reference 
laboratory (Singapore) for each serum 
sample against pandemic (H1N1) 
2009 virus (A/Auckland/1/2009) and 
seasonal inﬂ  uenza (H1N1) virus (A/
Brisbane/59/2007). The study was re-
viewed and approved by the National 
Healthcare Group Domain-Speciﬁ  c 
Review Board (ref no. E/09/289, 
J.W.T. principal investigator).
Mean ± SD age of participants 
was 60.1 ± 7.4 years (range 45–82 
years); 31 (62%) were women, 42 
(84%) were born in Singapore (the rest 
in Hong Kong, Malaysia, or India), 
and 26 (52%) had not traveled outside 
Singapore. None of the 50 partici-
pants had HI or MN titers >40 against 
inﬂ  uenza  A/Auckland/1/2009  when 
samples were tested in either labora-
tory. In contrast, 18 samples had either 
HI or MN titers >40 against seasonal 
inﬂ  uenza A/Brisbane/59/2007 (Table). 
Use of guinea pig or turkey erythro-
cytes in HI assays had little effect on 
the results (Table). Thus, our results 
are similar to those of Chen et al. (3) 
and Itoh et al. (4) for this small cohort 
in that none of the participants 40–80 
years of age from Southeast Asia had 
cross-reactive antibodies to pandemic 
(H1N1) 2009 virus.
Although differences in popu-
lation demographics and laboratory 
methods used make comparisons 
between studies difﬁ  cult, one of the 
most striking observations from vari-
ous studies has been the higher levels 
of cross-reactive antibody titers in pre-
pandemic serum samples from older 
persons (>80 years of age) in western 
populations (United States and United 
Kingdom) (5,6) than from persons  in 
eastern populations (China) (3) and 
Singapore (this study). Although Itoh 
et al (4) did not ﬁ  nd serologic cross-
reactivity in the population <80 years 
of age in Japan, they found higher 
levels of cross-reactive antibodies in 
their population >80 years of age. His-
torically, because epidemiologic data 
suggest that inﬂ  uenza (H1N1)/1918–
like viruses were widespread in Asia, 
these contrasting results are a stimulus 
for additional large-scale studies to as-
sess the effect of these viruses in these 
populations.   
Although the main limitation of 
our study is the small sample size, 
several reasons may account for dif-
ferent  ﬁ  ndings in population studies 
of serologic cross-reactivity. First, 
populations may not be comparable 
in terms of geographic proximity and 
their potential for community-ac-
quired infection within the same wave 
of a seasonal inﬂ  uenza epidemic with 
a virus that was similar to pandemic 
(H1N1) 2009 virus. Chen et al. (3) re-
ported that their serum samples were 
obtained mainly from rural farmers 
in China who lived farther apart than 
city dwellers, However, Hancock et 
al. (5) reported that their samples were 
obtained from vaccine trials conduct-
ed in 1976 or 2005–2009 involving 
academic, government, and industrial 
workers, which likely indicates that 
these persons were urban-based (i.e., 
living and working more closely to 
each other than rural farmers in Chi-
na). Thus, results of our study may 
not be directly comparable with either 
of these previous studies because our 
population resided in Southeast Asia 
and was urban-based.
Second, use of seasonal inﬂ  uenza 
vaccine has varied in different popula-
tions, with Singapore having one of the 
lowest recorded use rates in the West-
ern Paciﬁ  c region, and far lower than 
that in the United States (6). If previ-
ous seasonal inﬂ  uenza viruses shared 
a degree of antigenic cross-reactivity 
with pandemic (H1N1) 2009 virus, 
contemporary seasonal inﬂ  uenza vac-
cines, if well-matched, should reﬂ  ect 
changing antigenicity of seasonal 
inﬂ   uenza viruses; thus, vaccinated 
populations may have acquired some 
serologic cross-reactivity through pre-
vious inﬂ  uenza vaccines. However, it 
is likely that past infection rather than 
vaccination results in cross-reactivity, 
as suggested by Miller et al. (7).
Third, because pandemic (H1N1) 
2009 virus originated mainly from 
swine viruses in North America and 
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Table. Cross-reactive antibody titers to pandemic (H1N1) 2009 and seasonal influenza viruses for 50 persons, Singapore, May–
October 2009* 
Patient age, 
y/sex 
Laboratory 1 (Singapore General Hospital)  Laboratory 2 (WHO, Melbourne)
+
A/Auckland/1/2009 A/Brisbane/59/2007 A/Auckland/1/2009 A/Brisbane/59/2007 
HI† MN HI† MN HI‡ HI† HI‡
45/F <10 <10 <10 <10 <10 <10 <10
52/F <10 10 10 10 <10 10 <10
52/F <10 <10 10 <10 <10 <10 <10
52/F <10 <10 10 <10 <10 <10 <10
53/M <10 <10 10 <10 <10 <10 <10
53/F <10 <10 20 40 <10 <10 40
53/F <10 <10 160 80 <10 <10 160
53/M <10 <10 10 <10 <10 <10 <10
53/F <10 <10 160 320 <10 <10 160
53/F <10 <10 10 <10 <10 <10 <10
54/F <10 <10 10 <10 <10 <10 <10
54/M 10 <10 10 <10 <10 20 <10
55/F <10 <10 10 <10 <10 10 <10
55/F <10 <10 160 40 <10 <10 160
55/M <10 <10 10 <10 <10 <10 <10
56/F <10 <10 20 10 <10 <10 10
56/F <10 <10 80 80 <10 20 40
56/F <10 10 10 40 <10 <10 10
56/F <10 <10 10 <10 <10 <10 <10
5 7 / M 1 02 0 4 04 0 2 0 2 0 < 1 0
58/M <10 <10 20 20 <10 10 20
58/F <10 <10 40 20 <10 <10 80
59/M <10 <10 10 <10 <10 <10 <10
59/M <10 <10 20 20 20 20 10
59/F <10 <10 40 40 <10 <10 40
60/M <10 <10 80 40 <10 <10 80
60/M <10 <10 20 10 <10 <10 20
60/F 10 <10 10 <10 NR  <10 <10
61/F 10 <10 10 <10 <10 10 <10
61/M 10 <10 160 160 <10 <10 320
61/M <10 <10 <10 <10 <10 <10 <10
61/F <10 <10 10 <10 <10 <10 <10
62/F <10 20 10 20 NR  NR  NR 
62/F 10 10 80 20 <10 <10 40
62/F <10 <10 20 10 <10 20 40
62/F <10 <10 80 40 <10 <10 80
63/M <10 <10 80 40 <10 <10 80
63/F <10 <10 10 <10 <10 <10 <10
63/M <10 <10 40 20 <10 <10 20
63/M <10 <10 40 80 <10 <10 20
64/F 10 <10 20 10 <10 10 10
65/F 10 <10 10 <10 <10 20 <10
66/M <10 <10 <10 <10 <10 <10 <10
68/M <10 <10 40 80 <10 <10 40
71/F 10 10 10 20 <10 <10 <10
72/F <10 20 10 20 10 10 <10
75/M <10 <10 10 10 <10 20 <10
76/M <10 <10 40 20 <10 <10 40
78/F <10 10 10 20 <10 <10 <10
82/F 10 10 20 10 <10 20 <10
*WHO, World Health Organization; HI, hemagglutination inhibition; MN, microneutralization; NR, no results (because of insufficient serum).  
†Tested with guinea pig erythrocytes.  
‡Tested with turkey erythrocytes. LETTERS
Europe (8), resident populations in 
these countries have been exposed to 
these virus lineages more frequently 
than populations in Asia, and therefore 
may have acquired a greater degree of 
preexisting cross-reactive immunity 
to pandemic (H1N1) 2009 virus. A re-
cent review of human swine inﬂ  uenza 
infections suggests that they may not 
be uncommon (9), although the true 
incidence of human infections with 
swine inﬂ  uenza is unknown because 
of paucity of swine inﬂ  uenza surveil-
lance data worldwide (8).
In conclusion, partial cross-immu-
nity and cell-mediated immunity may 
be present but not detected by HI or 
MN assays. Thus, results of standard 
serologic assays may not be providing 
all relevant data (10).
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Molecular 
Epidemiology of 
Japanese 
Encephalitis 
Virus, Taiwan 
To the Editor: Japanese encepha-
litis virus (JEV) is a mosquito-borne 
member of the family Flaviviridae and 
the genus Flavivirus. JEV is a major 
cause of viral encephalitis in Asia. Phy-
logenetic analysis of the envelope (E) 
gene sequences has shown that JEV 
strains can be clustered into 5 distinct 
genotypes (1). Among them, genotype 
III (GIII) has had the widest geographic 
distribution in countries in Asia, in-
cluding Japan, South Korea, People’s 
Republic of China, Taiwan, Vietnam, 
the Philippines, and India (2). Before 
1990, GIII had been the major epidem-
ic JEV type in these areas. However, 
the introduction of JEV genotype I (GI) 
has been reported in Japan, Vietnam, 
South Korea, Thailand, and China in 
the past decade (3–6). Nabeshima et al. 
recently reported surveillance results 
that provided substantial evidence of 
frequent introductions of JEV GI into 
Japan from Southeast Asia and con-
tinental eastern Asia (7). Because all 
current vaccines are derived from JEV 
GIII strains, the effectiveness of vacci-
nation in inducing protective neutraliz-
ing antibodies against various genotype 
strains needs to be carefully evaluated, 
taking into account genotype shift in 
these countries.
Japanese encephalitis is endemic 
in Taiwan. Reports on the molecular 
epidemiology of JEV in Taiwan are 
scarce. Jan et al. (8) reported the ge-
netic variation of 47 JEV isolates from 
Taiwan before 1994. Phylogenetic 
analysis showed that all Taiwanese 
isolates were GIII, and they were clas-
siﬁ  ed into 3 clusters. 
To understand the genetic varia-
tion of JEV strains currently circulat-
ing in Taiwan, we conducted a surveil-
lance program in the following areas: 
northern (Taipei, Taoyuan, and Yilan 
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